Due to “Apparent Loophole” in Statutory Framework, District Court Permits Invalidity Challenge that Does Not Foreclose Later IPR

Apr 15, 2020

Reading Time : 2 min

Epic Games originally filed a complaint for declaratory judgment of non-infringement—but not of invalidity—challenging several of Acceleration Bay’s patents. After Acceleration Bay filed its counterclaims of patent infringement, Epic Games filed counterclaims-in-reply seeking declaratory judgment of patent invalidity (of the same patents that were the subject of the original complaint). Acceleration Bay moved to strike Epic Games’ invalidity counterclaims-in-reply. Acceleration Bay argued that allowing Epic Games’ invalidity counterclaims-in-reply would be an end-run around the rules governing the availability of IPRs.

In analyzing the motion to strike, the court noted that there are two statutes that prevent an accused infringer from taking a “second bite at the apple” after challenging the validity of a patent at the district court. First, under 35 U.S.C. § 315(a)(1), no IPR may be instituted if, prior to filing its petition, the petitioner sought a declaratory judgment of invalidity of the challenged patent. Second, under 35 U.S.C. § 315(b), no IPR may be instituted if the petition was filed more than one year after the petitioner (or a real party-in-interest or privy) was served with a complaint alleging infringement of the challenged patent.

In analyzing the issues, the court noted that Section 315(a)(3) states that a counterclaim challenging the validity of a patent claim “does not constitute a civil action challenging the validity of a claim of a patent” for purpose of Section 315(a)(1). The court also noted the Patent Trial and Appeal Board (PTAB) has held that counterclaims-in-reply are not subject to the bar under § 315(a)(3) because they are not “civil actions” challenging validity. See Canfield Scientific, Inc. v. Melanoscan, LLC, IPR2017-02125 Paper 15, 2018 WL 1628565, at *2-3 (PTAB Mar. 30, 2018).

Ultimately, the court allowed Epic Games’ invalidity counterclaims-in-reply. The court reasoned that striking them would be futile because the court was going to hear the invalidity challenges through Epic Games’ affirmative defenses anyway.

In its penultimate paragraph, the court explicitly recognized that by allowing the invalidity counterclaims-in-reply, Epic Games was able to take advantage of an “apparent loophole” left by the statutory scheme governing IPRs. The court stated that “unlike a patent infringement defendant (which cannot bring an IPR more than one year after being sued) or a declaratory judgment plaintiff seeking a judgment of invalidity (which cannot seek an IPR at all), a declaratory judgment counterclaimant faces no apparent restrictions on seeking an IPR.”  According to the court, this result could, in theory, allow a declaratory judgment counterclaimant to fully litigate the issue of patent validity in the district court, lose on the issue, and then seek a “redo” before the PTAB “while being subject to no estoppel or time limit whatsoever.”  The court recognized that this result cannot be reconciled with the clear congressional intent to limit the availability of IPRs to litigants, but that issue is “one for Congress to resolve.”

Practice Tip:  Potential infringers who wish to litigate validity in district court—while keeping intact their ability to challenge patentability at the PTAB—should consider seeking first a declaratory judgment of non-infringement. If that case proceeds, the patent holder will have to file a counterclaim of infringement or lose its ability to bring such a claim.  That will allow the declaratory judgment plaintiff to litigate validity either through affirmative defenses in its answer to that compulsory counterclaim, or through declaratory judgment counterclaims-in-reply, neither of which—according to this district court decision—should foreclose a later petition for IPR.

Epic Games, Inc. v. Acceleration Bay LLC, 4-19-cv-04133 (N.D. Cal. Apr. 1, 2020)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.